Tesamorelin 5mg
Modified GHRH analog — 44 amino acids with N-terminal trans-3-hexenoic acid modification Lipophilic modification protects against aminopeptidase degradation in experimental models Research-grade · CAS 218949-48-5 For in vitro GHRH receptor research only
For laboratory research use only. Not for human or veterinary consumption. SKU TSM5.
Product details.
Specifications
| Amino Acids | 44 |
| Modification | N-terminal trans-3-hexenoic acid |
| Molecular Weight | 5135.83 g/mol |
| CAS Number | 218949-48-5 |
| Form | Lyophilized powder |
| Quantity | 5mg per vial |
Three ways to stabilize GHRH
Sermorelin: no modifications, short half-life (~11 min), clean pulsatile release. CJC-1295 No DAC: four amino acid substitutions, moderate half-life (30 min-2 hours). Tesamorelin: full-length sequence with lipophilic N-terminal cap. Three different engineering philosophies applied to the same receptor target. Heritage Labs USA stocks all three.
Research context
Protease assays have confirmed that the trans-3-hexenoic acid group provides effective aminopeptidase resistance. Published studies have examined Tesamorelin in pituitary GHRH receptor signaling, somatotroph response kinetics, and head-to-head comparisons with Sermorelin and CJC-1295.
Frequently paired with
- Ipamorelin 5mg — Available as Ipa/Tesa Blend.
Storage
- Lyophilized: -20°C
- Reconstituted: 2-8°C, use within 30 days
For laboratory research use only. Not for human or veterinary use.
Technical reference adapted from the original Heritage Labs USA product listing. This description is not a certificate of analysis or evidence of testing for inventory supplied by this store.
